NCT06876714
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06876714
Title ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Alliance for Clinical Trials in Oncology
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.